US Stock MarketDetailed Quotes
INO Inovio Pharmaceuticals
- 10.3400
- -0.0300-0.29%
Trading Apr 24 11:12 ET
267.87MMarket Cap-1697P/E (TTM)
10.7800High10.2200Low86.89KVolume10.4200Open10.3700Pre Close912.69KTurnover0.34%Turnover RatioLossP/E (Static)25.91MShares14.748052wk High2.28P/B263.97MFloat Cap3.888052wk Low--Dividend TTM25.53MShs Float2352.0000Historical High--Div YieldTTM5.40%Amplitude3.8880Historical Low10.5030Avg Price1Lot Size
Inovio Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -91.89%832.01K | -17.66%102.65K | -95.76%388.45K | -71.19%225.97K | -42.26%114.94K | 478.23%10.26M | -85.14%124.67K | 3,038.22%9.15M | 187.51%784.4K | -46.36%199.07K |
| Operating revenue | -91.89%832.01K | -17.66%102.65K | -95.76%388.45K | -71.19%225.97K | -42.26%114.94K | 478.23%10.26M | -85.14%124.67K | 3,038.22%9.15M | 397.37%784.4K | 122.27%199.07K |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -51.68%134.26M | -50.96%27.5M | -43.38%25.43M | -64.48%37.27M | -38.74%44.07M | -8.30%277.84M | -47.28%56.07M | -25.45%44.91M | 25.69%104.92M | 35.91%71.93M |
| Selling and administrative expenses | -47.24%47.58M | -26.58%10.24M | -16.06%9.93M | -72.09%13.52M | -12.93%13.89M | 67.78%90.19M | -0.70%13.95M | -10.13%11.82M | 282.56%48.46M | 14.93%15.95M |
| -General and administrative expense | -47.24%47.58M | -26.58%10.24M | -16.06%9.93M | -72.09%13.52M | -12.93%13.89M | 67.78%90.19M | -0.70%13.95M | -10.13%11.82M | 282.56%48.46M | 14.93%15.95M |
| Research and development costs | -53.81%86.68M | -59.04%17.25M | -53.14%15.5M | -57.95%23.74M | -46.09%30.18M | -24.71%187.65M | -54.37%42.12M | -29.73%33.09M | -20.26%56.46M | 43.37%55.98M |
| Operating profit | 50.13%-133.43M | 51.04%-27.39M | 29.97%-25.04M | 64.43%-37.04M | 38.73%-43.95M | 11.17%-267.57M | 46.97%-55.95M | 40.36%-35.76M | -25.16%-104.14M | -36.49%-71.73M |
| Net non-operating interest income expense | 95.87%6.91M | -2.44%1.54M | 54.45%1.63M | 240.83%1.85M | 431.45%1.89M | 147.30%3.53M | 275.83%1.58M | 262.98%1.05M | 17.94%544.18K | 39.08%356.33K |
| Non-operating interest income | 70.08%8.13M | -3.69%1.82M | 41.95%1.94M | 152.81%2.17M | 229.52%2.21M | 42.19%4.78M | 109.99%1.89M | 78.23%1.37M | -7.59%857.67K | -12.92%669.81K |
| Non-operating interest expense | -2.49%1.22M | -9.94%282.33K | 0.00%313.49K | 0.00%313.49K | 0.00%313.49K | -35.24%1.25M | -34.73%313.49K | -34.19%313.49K | -32.83%313.49K | -38.90%313.49K |
| Other net income (expense) | 36.79%-8.6M | 1,024.61%853.29K | -241.51%-10.52M | 92.90%-348.18K | 125.47%1.41M | -296.37%-13.61M | 95.03%-92.29K | -508.78%-3.08M | -916.55%-4.9M | -231.36%-5.53M |
| Gain on sale of security | 174.57%5.85M | -30.99%1.93M | 88.04%-219.34K | 123.26%922.94K | 166.48%3.22M | -143.46%-7.85M | 235.93%2.79M | -302.65%-1.83M | -3,006.45%-3.97M | -470.86%-4.84M |
| Earnings from equity interest | 140.70%773.15K | -74.70%-214.61K | 170.27%214.37K | 116.78%156.75K | 214.67%616.64K | -243.16%-1.9M | -711.62%-122.85K | -1,286.70%-305.06K | -434.99%-934.02K | 35.25%-537.73K |
| Special income (charges) | ---10.51M | --0 | ---10.51M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| -Less:Impairment of capital assets | --10.51M | --0 | --10.51M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Other non- operating income (expenses) | -22.01%-4.71M | 68.86%-860.91K | 100.30%2.85K | -46,746.03%-1.43M | -1,480.57%-2.43M | -1,224.61%-3.86M | -1,656.49%-2.76M | -3,202.60%-940.78K | -101.65%-3.05K | -1,809.38%-153.47K |
| Income before tax | 51.34%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 47.15%-40.65M | 8.43%-277.65M | 49.07%-54.46M | 37.20%-37.78M | -32.09%-108.5M | -42.51%-76.91M |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | --0 | --0 | --0 | --0 | --0 | -398.45%-2.17M | --0 | --0 | --0 | -398.45%-2.17M |
| Net income | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M | 37.20%-37.78M | -32.09%-108.5M | -45.35%-79.07M |
| Net income continuous Operations | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M | 37.20%-37.78M | -32.09%-108.5M | -45.35%-79.07M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M | 37.20%-37.78M | -32.09%-108.5M | -45.35%-79.07M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M | 37.20%-37.78M | -32.09%-108.5M | -45.35%-79.07M |
| Basic earnings per share | 56.72%-6.09 | 58.82%-1.05 | 13.33%-1.56 | 71.74%-1.56 | 55.56%-1.92 | 19.37%-14.07 | 57.85%-2.55 | 48.28%-1.8 | -17.95%-5.52 | -33.33%-4.32 |
| Diluted earnings per share | 56.72%-6.09 | 58.82%-1.05 | 13.33%-1.56 | 71.74%-1.56 | 55.56%-1.92 | 19.37%-14.07 | 57.85%-2.55 | 48.28%-1.8 | -17.95%-5.52 | -33.33%-4.32 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg